Navigation Links
NYP/Weill Cornell physician-scientists present latest cancer findings at ASCO meeting
Date:5/31/2008

NEW YORK (May 29, 2008) -- Leading oncologists and cancer researchers at NewYork-Presbyterian Hospital/Weill Cornell Medical Center are presenting new basic and clinical research findings at the 44th American Society of Clinical Oncology (ASCO) annual meeting in Chicago, May 30 to June 3.

Highlights from the symposium presentations and posters to be made by NewYork-Presbyterian/Weill Cornell physician-scientists include the following:

Phase II trial of 177Lutetium radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 in patients with metastatic castrate-resistant prostate cancer. [Abstract number: 5140; Poster number: 13H]

Time: Saturday, May 31. 8:00 a.m. 12:00 p.m.
Authors: S. T. Tagawa, M. I. Milowsky, M. J. Morris, S. Vallabhajosula, S. Goldsmith, D. Matulich, J. Kaplan, F. Berger, H. I. Scher, N. H. Bander, D. M. Nanus

Drs. Scott Tagawa, Neil Bander and their colleagues at NewYork-Presbyterian/Weill Cornell will present data from a Phase II clinical trial showing that a monoclonal antibody designated "J591," carrying a payload of a radioactive isotope (177Lu), is both safe and effective in the treatment of late-stage metastatic prostate cancer. The antibody works by targeting only prostate cancer cells anywhere in the body while leaving the healthy cells around them unharmed. Patients in this trial had progressing, hormone-independent, metastatic prostate cancer with rapidly increasing prostate specific antigen (PSA) levels. Following only one dose of the J591 antibody loaded with the maximum radiation dose, PSA levels fell in two-thirds of patients with half of all the patients achieving a significant threshold of at least a 30-percent PSA decline. The 30-percent PSA decline threshold has been shown in two large, independent registration trials to be the best PSA surrogate for survival benefit. Additionally, the clinician-scientists found that none of the patients developed s
'/>"/>

Contact: Andrew Klein
ank2017@med.cornell.edu
212-821-0560
New York- Presbyterian Hospital/Weill Cornell Medical Center/Weill Cornell Medical College
Source:Eurekalert

Page: 1 2 3 4

Related medicine news :

1. NYP/Weill Cornell gene therapy clinical trial yields promising results for Batten disease
2. NIH selects Weill Cornell Medical College to lead new NYC translational research collaboration
3. Healthy restaurants help make us fat, says a new Cornell study
4. The latest about male infertility and testosterone from NewYork-Presbyterian/Weill Cornell
5. White House awards Weill Cornells Bruce McCandliss highest honor for early career scientists
6. Weill Cornell receives $2.4 million in grants from Gates Foundation to fight tuberculosis
7. NewYork-Presbyterian/Weill Cornell creates world-class cancer center
8. By color-coding atoms, new Cornell electron microscope promises big advance in materials analysis
9. $50 million gift to NewYork-Presbyterian Hospital/Weill Cornell Medical Center
10. Weill Cornell team identifies potential new drug targets against hormone-dependent breast cancer
11. Weill Cornell receives funding to study creation of new elder abuse center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... , ... September 02, 2015 , ... ... Things, announces its latest addition to its screen mirroring and extending product line ... Extended Wireless Display, which operates in local WIFI setting, the new Splashtop Wired ...
(Date:9/2/2015)... Pune (PRWEB) , ... September 02, 2015 , ... The ... USD 10.3 billion in 2015, at a CAGR of 5.2%. The global medical waste ... and geography. The treatment and disposal segment is expected to register the highest growth ...
(Date:9/2/2015)... ... September 02, 2015 , ... A UPMC and ... earned international recognition as a premier center for treatment of and research into ... internal bleeding and stroke. , Cure HHT, previously known as The HHT ...
(Date:9/2/2015)... , ... September 02, 2015 , ... ... Center at Children's Healthcare of Atlanta to help support childhood cancer research. ... the upcoming WSB Radio Care-A-Thon , which is the fund-raising event DoMyOwnPestControl.com ...
(Date:9/2/2015)... WI (PRWEB) , ... September 02, 2015 , ... ... Cypress Benefit Administrators is taking action after seeing a significant increase ... TPA’s Argus Claim Review division has found many cases of OON ASCs encouraging ...
Breaking Medicine News(10 mins):Health News:Splashtop Launches Wired XDisplay, the Fastest Screen Sharing Solution for Extending and Mirroring Your Computer Screen to Mobile Devices 2Health News:Splashtop Launches Wired XDisplay, the Fastest Screen Sharing Solution for Extending and Mirroring Your Computer Screen to Mobile Devices 3Health News:Medical Waste Management Market Growing at 5.2% CAGR to 2020 2Health News:Medical Waste Management Market Growing at 5.2% CAGR to 2020 3Health News:Medical Waste Management Market Growing at 5.2% CAGR to 2020 4Health News:Medical Waste Management Market Growing at 5.2% CAGR to 2020 5Health News:UPMC-University of Pittsburgh Named Center of Excellence for Rare Disorder 2Health News:UPMC-University of Pittsburgh Named Center of Excellence for Rare Disorder 3Health News:UPMC-University of Pittsburgh Named Center of Excellence for Rare Disorder 4Health News:DoMyOwnPestControl.com Goes Gold for Childhood Cancer Awareness Month 2Health News:TPA Cracks Down on Forbidden Tactics Used by Out-of-Network Surgical Centers 2Health News:TPA Cracks Down on Forbidden Tactics Used by Out-of-Network Surgical Centers 3
... Inc. (Phyhealth) (Pink Sheets: PHYH), a developer of,health ... the signing of a $250,000 Note with The ... working capital to support,its general corporate regulatory and ... an additional $3,500,000 in cash, which is,designated for ...
... Approves Entry into Clinical Trials on Schedule, ... -- China,Pharma Holdings, Inc. ("China Pharma") (OTC ... generic and branded bio-pharmaceutical,products in China, announced ... been granted approval by China,s State Food ...
... Mass., Oct. 29 Boston Scientific,Corporation (NYSE: BSX ... of the U.S. armed forces and service veterans better ... Care Act of 2008 was included in the National ... law by the,President. The legislation, introduced by Representative Dave ...
... -, PITTSBURGH, Oct. 29 Mylan Inc. (NYSE: ... India-based,subsidiary in which it holds a 71.5% controlling interest, ... mg and 200 mg, with the,filing of its Abbreviated ... against Matrix within the 45-day time period provided by ...
... Irvine Pharmaceutical Services,Inc., announced today that as part ... future industry demands, the company has promoted Aryo,Nikopour to ... its staff Chief Operating Officer Greg McParland. These changes ... it gears up to launch its new,subsidiary, Avrio Biopharmaceuticals, ...
... Products, According ... from HealthLeaders-InterStudy, NASHVILLE, Tenn., Oct. 29 HealthLeaders-InterStudy, ... despite,its trend-setter reputation, California is behind the curve in ... as,insurers search for the right price for their products. ...
Cached Medicine News:Health News:Phyhealth Completes $250,000 Funding 2Health News:China Pharma Holdings, Inc. to Initiate Clinical Trials For New Antibiotic Combination 2Health News:China Pharma Holdings, Inc. to Initiate Clinical Trials For New Antibiotic Combination 3Health News:Boston Scientific Welcomes Passage of Federal Pain Care Legislation to Benefit Military Members and Veterans 2Health News:Boston Scientific Welcomes Passage of Federal Pain Care Legislation to Benefit Military Members and Veterans 3Health News:Boston Scientific Welcomes Passage of Federal Pain Care Legislation to Benefit Military Members and Veterans 4Health News:Mylan's Matrix First-to-File on Generic Version of Vfend(R) Antifungal 2Health News:Irvine Pharmaceutical Services Enhances Staff, Prepares for Innovative Expansion 2Health News:California Insurers are Behind the Curve with Consumer-Driven Health Plans 2
(Date:9/2/2015)... 2015  The report on breast cancer therapeutics: pipeline ... drugs on the basis of the molecules which are ... inner lining of milk ducts or lobules responsible for ... tumor that can spread to other cells present in ... lobules is referred as lobular carcinoma, while the other ...
(Date:9/2/2015)... The quantum dot market report analyzes the ecosystem of the ... product includes medical devices, display, and others. The others segment ... storage, QD laser, and transistor. The application segment covers the ... The report also provides the geographic view for major regions ... Europe , Asia-Pacific (APAC), and ...
(Date:9/2/2015)... NEW YORK , Sept. 2, 2015 /PRNewswire/ ... dystrophy is an X-linked disease, which generally affects ... muscle degeneration and weakness. The disease is caused ... result in the lack of production of dystrophin ... in individuals. The lack of dystrophin weakens muscle ...
Breaking Medicine Technology:Breast Cancer Therapeutics: Pipeline Analysis Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023 2Breast Cancer Therapeutics: Pipeline Analysis Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023 3Quantum Dot Market by Product , Material, Application, and Geography- Forecast up to 2020 2Global Duchenne Muscular Dystrophy Drugs Market 2015-2019 2Global Duchenne Muscular Dystrophy Drugs Market 2015-2019 3
... (Nasdaq: ALTH ) today announced the initiation ... multi-center dose,escalation study of the Company,s targeted chemotherapeutic ... non-Hodgkin,s lymphoma (NHL). "We are pleased to ... Cagnoni, M.D., Chief Medical Officer of Allos. "RH1 ...
... Appropriate Patient Selection Criteria for Future Field ... ... Corporation (Nasdaq: DVAX ) presented yesterday a detailed,analysis of data ... for ragweed allergic rhinitis. The,data were reported yesterday at the annual ...
Cached Medicine Technology:Allos Therapeutics Initiates Study of RH1 in Patients with Advanced Solid Tumors or non-Hodgkin's Lymphoma 2Allos Therapeutics Initiates Study of RH1 in Patients with Advanced Solid Tumors or non-Hodgkin's Lymphoma 3Allos Therapeutics Initiates Study of RH1 in Patients with Advanced Solid Tumors or non-Hodgkin's Lymphoma 4Dynavax Presents New Analysis of TOLAMBA(TM) Data at ACAAI Meeting 2Dynavax Presents New Analysis of TOLAMBA(TM) Data at ACAAI Meeting 3
Full Handle Laseredge Implant Blade Knife, 5.2 mm round tip. Blade dimension: 16.5 mm x 5.2 mm x 3.8 mm x 2.4 mm....
Full Handle Laseredge Implant Blade Knife, 5.2 mm angled bevel up. Blade dimension: 16.5 mm x 5.2 mm x 4.2 mm x 1.6 mm....
Full Handle Laseredge Implant Blade Knife, 4.0 mm straight. Blade dimension: 15.2 mm x 4.0 mm x 3.0 mm x 1.6 mm....
Full Handle Laseredge Crescent Blade Knife, straight. Blade tip dimension: 12.7 mm x 2.0 mm x 3.8 mm....
Medicine Products: